### Methodology


MAYA proposes the integration of advanced monitoring systems, Al-driven data analysis, and participatory research, through innovative Social Sciences and Humanities methods such as:


multistakeholder engagement



### **EU Cancer Mission**


MAYA objectives align with the goals of the Mission on Cancer by contributing to:












Funded under the Horizon Europe - Research and Innovation programme, MAYA is a 4-year **project** coordinated by the University of Ioannina, Greece, and brings together a consortium of 16 partners from 10 countries: medical & technological universities, oncology hospitals, companies, foundations, research centers, patient associations, manufacturers of smart mirrors technology.






































contact@maya-horizon.eu





Funded by the European Union

Funded by the European Union's Horizon Europe programme under grant agreement 101213323. Views and opinions expressed are however those of the author(s) only and do not

necessarily reflect those of the European Health and Digital Executive Agency, Neither the European Union nor the granting authority can be held responsible for them.



smart Mirrors supporting healthier lives of Adolescents and Young Adults after cancer



**Empowering young cancer** survivors to take control of their cardiovascular health through Al-driven, personalised care

maya-horizon.eu

### Aim

The MAYA project aims to empower Adolescents and Young Adults (AYA) cancer survivors to manage their cardiovascular health through digital tools, particularly addressing cardiotoxic-related late effects of cancer treatment.

The project envisions using the iCARE health hub, which integrates a smart mirror and an Alpowered conversational agent, to deliver personalised care and continuous monitoring.



# Prevention of late-onset cardiovascular complications

The project's main objective is to reduce the risk of major cardiac events in AYA cancer survivors by 30-40% by addressing modifiable risk factors such as hypertension, diabetes and obesity, ultimately improving both cardiovascular outcomes and quality of life

#### **Context**

AYA can develop various cancers, often requiring treatments such as chemotherapy, hormone therapy, targeted therapy, immunotherapy, radiation, and surgery.

Common long-term effects of these treatments include:



cardiovascular toxicity (up to 22%)



secondary cancers



reduced quality of life



mental health problems



chronic fatique



neurocognitive issues



fertility and endocrine disorders

Late-onset cardiovascular toxicities can be subclinical (no symptoms initially) or clinical (with symptoms) and are a leading cause of non-cancer morbidity and mortality in long-term cancer survivors.

Early intervention and lifelong surveillance are crucial in preventing disease progression

## Digital Health Approach

Al-driven digital health technologies for personalised and context-aware interactions can effectively prevent, monitor, and manage cardiovascular late effects in AYA cancer survivors



MAYA improves modifiable cardiovascular risk factors by leveraging intelligent conversational agents and advanced digital tools, with:

- The iCARE health hub, equipped with a smart mirror and an Al-powered conversational agent.
- The iCARE health hub is designed to monitor and manage late-onset cardiovascular health issues and address gaps in care during the transition to post-treatment stages.
- Additionally, they improve health literacy by providing coaching, helping survivors understand and overcome barriers to managing their health.
- By installing these tools in homes, we will assess the impact and receptiveness of these technologies in different European countries.